Skip to content
2000
Volume 20, Issue 20
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Alois Alzheimer identified first abnormal deformation in the brain of diseased people with mental disorder. The disorder is clinically characterized by a progression from episodic memory problems to a slow global decline of cognitive function, ending with the final stage when patients become bedridden and death occurs on average 9 years after diagnosis. The current standard of care does not cover the approved and effective treatment of both cognitive and non-cognitive symptoms. Tremendous effort was put in investigation of the disease development. The uncovered molecular mechanism shed light on aspartic proteases, the smallest protease class with about 15 members in the human genome. Here we summarise the most important structure-based developments on one of the most popular aspartic protease target BACE1.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/13816128113199990607
2014-05-01
2025-09-23
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/13816128113199990607
Loading

  • Article Type:
    Research Article
Keyword(s): Alzheimer disease; BACE1; structure-based drug design; virtual screening
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test